Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

Inclusion criteria: * subject is aged 2 months or older * subject has secondarily-infected traumatic lesion (laceration, sutured wound or abrasion) * negative urine pregnancy test * subject has total skin infection rating scale score of at least 8, including pus/exudate score of at least 3 * subject and/or parent/legal guardian is willing and able to comply with protocol * subject or parent/legal guardian has given written informed consent or assent as applicable Exclusion criteria: * previous hypersensitivity to pleuromutilin * secondarily-infected animal/human bite or puncture wound * subject has an abscess * chronic ulcerative lesion * underlying skin disease * systemic signs and symptoms of infection * infection not appropriately treated with topical antibiotic * infection requires surgical intervention prior to or during study * subject received systemic antibacterial or steroid, or topical therapeutic agent within 24 hours of entry into study * serious underlying disease * subject pregnant, breast feeding or planning a pregnancy, or unacceptable method of contraception * other investigational drug within 30 days of study entry * subject previously enrolled in this study